<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336074</url>
  </required_header>
  <id_info>
    <org_study_id>CCT-NAPN-24772</org_study_id>
    <secondary_id>2014-001425-32</secondary_id>
    <nct_id>NCT02336074</nct_id>
  </id_info>
  <brief_title>Research In Viral Eradication of HIV Reservoirs</brief_title>
  <acronym>RIVER</acronym>
  <official_title>Research In Viral Eradication of HIV Reservoirs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chelsea and Westminster NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Free Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brighton and Sussex University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central and North West London NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a two-arm prospective 1:1 randomised controlled trial comparing:

      Arm A: cART preferably including raltegravir (combination ART cART - control) Arm B: cART
      preferably including raltegravir (cART) plus ChAdV63.HIVconsv (ChAd) prime and MVA.HIVconsv
      (MVA) boost vaccines; followed by a 28-day course of vorinostat (10 doses in total).

      We hypothesise that this intervention in primary HIV infection will confer a significant
      reduction in the latent HIV reservoir when compared with cART alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a two-arm, open label randomised study. Eligible participants are
      recruited from two participant cohorts (Cohort I - Recently diagnosed or Cohort II -
      Previously diagnosed with HIV). All participants receive combination ART (cART) for the
      duration of the intervention phase of the study (Cohort I: 42 weeks, Cohort II: 18 weeks). In
      patients meeting the criteria for randomisation (eligibility assessed at week 22/screening),
      participants will either continue cART or receive an intervention consisting of two anti-HIV
      vaccines separated by 8 weeks followed by 10 doses of the HDACi, vorinostat, in addition to
      cART. We hypothesise that the prime-boost vaccination will result in the generation of
      vaccine induced HIV specific CTLs that will recognise HDACi-activated cells of the HIV
      reservoir and destroy them. The net effect will be a greater reduction in the HIV reservoir
      defined as HIV total DNA in CD4+ T-cells in the cART+vaccine+HDACi compared to the cART
      alone. Our strategy is entirely different from previous therapeutic vaccination approaches
      which have been largely unsuccessful. Immunological priming to conserved HIV proteins will
      drive CD8+ T-lymphocyte recognition of latently-infected cells rendered immunogenic by HDACi.
      We anticipate that the viral antigens expressed by latently-infected cells will be unable to
      adapt to, or escape from, the immune response as they will be expressed directly from
      chromosomal DNA, avoiding the steps of the viral life-cycle that facilitate immune-driven
      adaptation. We have chosen a prime-boost immunisation strategy with recombinant
      replication-defective chimpanzee adenovirus and modified vaccinia Ankara vectors, bearing
      conserved HIV antigens; these products have been shown to induce high titres of HIV-specific
      CD8+ T-cells. In addition, these vaccines will drive immune responses against conserved
      regions of the virus that may be well preserved in individuals with PHI.

      Primary HIV Infection (PHI) is a unique period when HIV proviral reservoir is smaller than in
      chronic disease, is likely to be more homogeneous than in later stage disease and hence is
      more susceptible to immunological elimination. This provides an opportunity to use a vaccine
      to re-direct HIV-specific immune responses towards genetically fragile regions in the viral
      proteome. Immunisation in PHI should result in potent immune responses because ART initiated
      in PHI preserves CD4 function and early ART-mediated viral suppression limits viral
      diversification, reducing the chance of immune escape. The other key reason for conducting
      this trial in patients treated in PHI is that, in some patients, an early sustained course of
      ART started very early in infection may induce a state of viral remission in which therapy
      can be stopped without any rebound viraemia. This has been most notably reported in the
      VISCONTI cohort in which 'post-treatment control' was identified in 15.6% of selected
      individuals.

      Data from our group and others has shown that whilst there is a rapid decline in measures of
      total HIV DNA following ART initiation up to 6 months after seroconversion this then plateaus
      out to approximately 2 years after diagnosis of acute infection. Hence randomisation of
      individuals starting immediate ART in acute infection have comparable levels of HIV
      reservoirs to those who have started treatment within a similar timeframe, but have remained
      on suppressive therapy for up to 2 years after initiation. Furthermore, since the primary
      endpoint of the RIVER study design compares total HIV DNA between the two arms from
      randomisation to post-randomisation weeks 16 &amp; 18 Cohorts I and II will be comparable.

      We hypothesise that the combination of HDACi with immunisation in cART-suppressed PHI will
      significantly impact the HIV reservoir.

        1. Patients in Cohort I - Recently diagnosed will receive combination antiretroviral
           therapy designed to reduce the plasma viral load as quickly as possible, hence the
           rationale for the preferred inclusion of raltegravir, an integrase inhibitor. Both
           cohorts will have been treated in PHI, which may restrict the size of the reservoir
           compared with people initiating ART in later stages of HIV infection. Cohort II -
           Previously diagnosed participants are screened the same as Cohort I and are maintained
           on ART throughout the study. The ART regimen is preferably a combination that includes
           raltegravir, as hypothetically, if vorinostat induced viral transcription an integrase
           inhibitor may protect uninfected cells. However, there is no evidence to support this
           hypothesis and the key inclusion criteria must be the continuation of a virally
           suppressive ART regimen throughout the study.

        2. The prime-boost vaccination is designed to enhance the killing capacity of the cytotoxic
           T cells. This must be given before the HDACi in order to prime and boost a maximal
           HIV-specific T-cell response to recognise activated viral antigen expression on
           reservoir cells.

        3. The HDACi is designed to cause viral transcription from latently infected cells;
           activate the reservoir, and in the presence of the enhanced killing capacity of the CD8+
           T cells, results in killing of the cells previously harbouring latent virus, leading to
           further reductions in the reservoir.

      This exact combined approach in treated PHI has never previously been used, we hypothesise
      there will be a 50% reduction in the proviral DNA (the 'reservoir'), in this
      'proof-of-concept' study, in those randomised to the vaccine-HDACi intervention compared to
      those receiving antiretroviral therapy alone.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 27, 2015</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total HIV DNA from CD4 T-cells</measure>
    <time_frame>Averaged across post-randomisation week 16 and 18</time_frame>
    <description>The average of two measures taken at post-randomisation week 16 and 18</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and laboratory adverse events</measure>
    <time_frame>42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further assessment of the HIV reservoir</measure>
    <time_frame>42 weeks</time_frame>
    <description>Further assessment of the HIV reservoir e.g. HIV integrated DNA; HIV cell associated RNA; plasma HIV RNA measured with an ultra-low copy assay i.e. with a threshold of &lt;1 copy/ml and viral outgrowth assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Studies of immune function</measure>
    <time_frame>42 weeks</time_frame>
    <description>Studies of immune function including measuring the latently-infected resting memory T-cells and cytotoxic immune responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma IL-6 (an inflammatory biomarker)</measure>
    <time_frame>42 weeks</time_frame>
    <description>Effectiveness of the treatment will be assessed by monitoring the levels of IL-6, an inflammatory biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma hCRP (an inflammatory biomarker)</measure>
    <time_frame>42 Weeks</time_frame>
    <description>Effectiveness of the treatment will be assessed by monitoring the levels of hCRP, an inflammatory biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma TNF-alpha (an inflammatory biomarker)</measure>
    <time_frame>42 Weeks</time_frame>
    <description>Effectiveness of the treatment will be assessed by monitoring the levels of TNF-alpha, an inflammatory biomarker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total) Plus ChAdV63.HIVconsv prime (post-randomisation week 00) and MVA.HIVconsv boost (post randomisation week 08 day 1) vaccines; followed by a 28-day course of vorinostat (10 doses in total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Antiretroviral Therapy (cART)</intervention_name>
    <description>Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).
Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdV63.HIVconsv (ChAd)</intervention_name>
    <description>Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA.HIVconsv (MVA)</intervention_name>
    <description>Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Aged ≥18 to ≤60 years old

          2. Able to give informed written consent including consent to long-term follow-up

          3. Should be enrolled within a maximum of 4 weeks of a diagnosis of primary HIV-1
             infection confirmed by one of the following criteria:

               1. Positive HIV-1 serology within a maximum of 12 weeks of a documented negative
                  HIV-1 serology test result (can include point of care test (POCT) using blood for
                  both tests)

               2. A positive p24 antigen result and a negative HIV antibody test

               3. Negative antibody test with either detectable HIV RNA or proviral DNA

               4. PHE RITA test algorithm (a) reported as &quot;Incident&quot; confirming the HIV-1 antibody
                  avidity is consistent with recent infection (within the preceding 16 weeks).

               5. Weakly reactive or equivocal 4th generation HIV antibody antigen test

               6. Equivocal or reactive antibody test with &lt;4 bands on western blot

          4. Adequate haemoglobin (Hb≥12g/dL for males, ≥11g/dL for females)

          5. Weight ≥50kg

          6. Willing to be treated with cART (preferably including raltegravir) and be randomised
             to continue cART alone or cART plus intervention (HIV vaccines plus HDACi)

          7. Willing and able to comply with visit schedule and provide blood sampling

        Exclusion criteria

          1. Women of child bearing potential (WCBP) (b)

          2. In women with intact ovaries and no uterus, any planned egg donation anytime in the
             future to a surrogate

          3. Intention to donate sperm or father a child within 6 months of the intervention

          4. Co-infection with hepatitis B (surface antigen positive or detectable HBV DNA levels
             in blood) or hepatitis C (HCV RNA positive or HVC antigen positive)

          5. Any current or past history of malignancy

          6. Concurrent opportunistic infection or other comorbidity or comorbidity likely to occur
             during the trial e.g.past history of ischaemic or other significant heart disease,
             malabsorption syndromes, autoimmune disease

          7. Any contraindication to receipt of BHIVA recommended combination antiretrovirals

          8. HIV-2 infection

          9. Known HTLV-1 co-infection

         10. Prior immunisation with any experimental HIV Immunogens (including any component of
             the vaccines used in the RIVER protocol; simian or human adenoviral vaccine; other
             experimental HIV vaccines)

         11. Current or planned systemic immunosuppressive therapy (inhaled corticosteroids are
             allowed)

         12. Any history of proven thromboembolism (pulmonary embolism or deep vein thrombosis)

         13. Any inherited or acquired bleeding diathesis including gastric or duodenal ulcers,
             varices

         14. Concurrent or planned use of any drugs contraindicated with vorinostat i.e.
             antiarrhythmics; any other drugs that prolong QTc; warfarin, aspirin, sodium valproate

         15. Prior intolerance of any of either the components of the vaccine or HDACi,

         16. Uncontrolled diabetes mellitus defined as an HBA1C&gt;7%

         17. Any congenital or acquired prolongation of the QTc interval, with normal defined as
             ≤0.44s (≤440ms)

         18. Participation in any other clinical trial of an experimental agent or any
             non-interventional study where additional blood draws are required; participation in
             an observational study is permitted

         19. Allergy to egg

         20. History of anaphylaxis or severe adverse reaction to vaccines

         21. Planned receipt of vaccines within 2 weeks of the first trial vaccination administered
             at PR week 00 (including vaccines such as yellow fever; hepatitis B, influenza)

         22. Abnormal blood test results at screening including:

               1. Moderate to severe hepatic impairment as defined by Child-Pugh classification

               2. ALT &gt;5xULN

               3. Platelets &lt;150x109/L

               4. eGFR &lt;60 (c)

               5. uPCR &gt;30 mg/mmol

         23. Physical and laboratory test findings: Evidence of organ dysfunction or any clinically
             significant deviation from normal in physical examination and/or vital signs that the
             investigator believes is a preclusion from enrolment into the study

         24. Active alcohol or substance use that, in the Investigator's opinion, will prevent
             adequate adherence with study requirements

         25. Insufficient venous access that will allow scheduled blood draws as per protocol

               1. using current cut-offs for optical density as defined by PHE

               2. females aged &lt;20 years of age, and weighing &lt;65kg and &lt;168cm in height will need
                  to have an estimation of blood volume (EBV) prior to enrolment, &gt;3500mL before to
                  participate. This circumstance is unlikely to arise as most women between the
                  ages of 18 to 20 years would be of child-bearing potential (CBP) and excluded on
                  that basis.

               3. eGFR is calculated by the local labs using CKD-EPI. Units ml/min/1.73m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Fidler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central and North West London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.cherub.uk.net/</url>
    <description>CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC) website</description>
  </link>
  <link>
    <url>http://www.ctu.mrc.ac.uk/</url>
    <description>Medical Research Council Clinical Trials Unit</description>
  </link>
  <reference>
    <citation>International AIDS Society Scientific Working Group on HIV Cure, Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, Telenti A, Van Lint C, Verdin E, Woolfrey A, Zaia J, Barré-Sinoussi F. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012 Jul 20;12(8):607-14. doi: 10.1038/nri3262. Review.</citation>
    <PMID>22814509</PMID>
  </reference>
  <reference>
    <citation>Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, Dinarello C, Østergaard L, Tolstrup M. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother. 2013 May;9(5):993-1001. doi: 10.4161/hv.23800. Epub 2013 Jan 31.</citation>
    <PMID>23370291</PMID>
  </reference>
  <reference>
    <citation>Richman DD. Introduction: challenges to finding a cure for HIV infection. Curr Opin HIV AIDS. 2011 Jan;6(1):1-3. doi: 10.1097/COH.0b013e328340ffa6. Review.</citation>
    <PMID>21242886</PMID>
  </reference>
  <reference>
    <citation>Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. Review.</citation>
    <PMID>16955068</PMID>
  </reference>
  <reference>
    <citation>Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 2010 Feb 23;5(2):e9390. doi: 10.1371/journal.pone.0009390.</citation>
    <PMID>20186346</PMID>
  </reference>
  <reference>
    <citation>Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem. 2009 Mar 13;284(11):6782-9. doi: 10.1074/jbc.M807898200. Epub 2009 Jan 9.</citation>
    <PMID>19136668</PMID>
  </reference>
  <reference>
    <citation>Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses. 2009 Feb;25(2):207-12. doi: 10.1089/aid.2008.0191.</citation>
    <PMID>19239360</PMID>
  </reference>
  <reference>
    <citation>Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, Cohen MS, Coffin JM, Bosch RJ, Gay CL, Eron JJ, Margolis DM, Perelson AS. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9523-8. doi: 10.1073/pnas.1120248109. Epub 2012 May 29.</citation>
    <PMID>22645358</PMID>
  </reference>
  <reference>
    <citation>Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.</citation>
    <PMID>22837004</PMID>
  </reference>
  <reference>
    <citation>Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012 Mar 23;36(3):491-501. doi: 10.1016/j.immuni.2012.01.014. Epub 2012 Mar 8.</citation>
    <PMID>22406268</PMID>
  </reference>
  <reference>
    <citation>Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ, Hanke T. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One. 2007 Oct 3;2(10):e984. Erratum in: PLoS One. 2011;6(3). doi: 10.1371/annotation/fca26a4f-42c1-4772-a19e-aa9d96c4eeb2.</citation>
    <PMID>17912361</PMID>
  </reference>
  <reference>
    <citation>Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol. 2011 Jun;23(3):377-82. doi: 10.1016/j.coi.2011.03.006. Epub 2011 Apr 20. Review.</citation>
    <PMID>21514130</PMID>
  </reference>
  <reference>
    <citation>Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M, Goudsmit J. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004 May 21;18(8):1213-6.</citation>
    <PMID>15166541</PMID>
  </reference>
  <reference>
    <citation>Tatsis N, Blejer A, Lasaro MO, Hensley SE, Cun A, Tesema L, Li Y, Gao GP, Xiang ZQ, Zhou D, Wilson JM, Ertl HC. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther. 2007 Mar;15(3):608-17. Epub 2007 Jan 16.</citation>
    <PMID>17228314</PMID>
  </reference>
  <reference>
    <citation>Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012 Jan 4;4(115):115ra2. doi: 10.1126/scitranslmed.3002925.</citation>
    <PMID>22218691</PMID>
  </reference>
  <reference>
    <citation>Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012 Jan 4;4(115):115ra1. doi: 10.1126/scitranslmed.3003155.</citation>
    <PMID>22218690</PMID>
  </reference>
  <reference>
    <citation>Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks MD, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011 Dec;19(12):2269-76. doi: 10.1038/mt.2011.176. Epub 2011 Aug 23.</citation>
    <PMID>21862998</PMID>
  </reference>
  <reference>
    <citation>Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B. 1978 Dec;167(5-6):375-90. German.</citation>
    <PMID>219640</PMID>
  </reference>
  <reference>
    <citation>Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol. 1998 Feb;79 ( Pt 2):347-52.</citation>
    <PMID>9472619</PMID>
  </reference>
  <reference>
    <citation>Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51.</citation>
    <PMID>1438287</PMID>
  </reference>
  <reference>
    <citation>Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, Sharpe SA, Cook N, Smith GL, Watkins DI, Cranage MP, McMichael AJ. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol. 1999 Sep;73(9):7524-32.</citation>
    <PMID>10438842</PMID>
  </reference>
  <reference>
    <citation>Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999 Feb 5;283(5403):857-60.</citation>
    <PMID>9933172</PMID>
  </reference>
  <reference>
    <citation>Barouch DH, Santra S, Kuroda MJ, Schmitz JE, Plishka R, Buckler-White A, Gaitan AE, Zin R, Nam JH, Wyatt LS, Lifton MA, Nickerson CE, Moss B, Montefiori DC, Hirsch VM, Letvin NL. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol. 2001 Jun;75(11):5151-8.</citation>
    <PMID>11333896</PMID>
  </reference>
  <reference>
    <citation>Hayton EJ, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A, Black AP, Dorrell L, Hanke T. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One. 2014 Jul 9;9(7):e101591. doi: 10.1371/journal.pone.0101591. eCollection 2014.</citation>
    <PMID>25007091</PMID>
  </reference>
  <reference>
    <citation>Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, Goh LE, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard PM, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper DA, Perrin L; QUEST Study Group. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis. 2005 Aug 15;192(4):607-17. Epub 2005 Jul 15.</citation>
    <PMID>16028129</PMID>
  </reference>
  <reference>
    <citation>Vanham G, Van Gulck E. Can immunotherapy be useful as a &quot;functional cure&quot; for infection with Human Immunodeficiency Virus-1? Retrovirology. 2012 Sep 7;9:72. doi: 10.1186/1742-4690-9-72. Review.</citation>
    <PMID>22958464</PMID>
  </reference>
  <reference>
    <citation>Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttill A, Conlon C, Brown D, Williams P, Bowness P, Goonetilleke N, Rostron T, Rowland-Jones S, Hanke T, McMichael A. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol. 2006 May;80(10):4705-16.</citation>
    <PMID>16641264</PMID>
  </reference>
  <reference>
    <citation>Hicks CB, Gay C, Ferrari G. Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses. Clin Exp Immunol. 2007 Aug;149(2):211-6. Epub 2007 Jun 21. Review.</citation>
    <PMID>17590167</PMID>
  </reference>
  <reference>
    <citation>Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 2012 Feb;8(2):e1002506. doi: 10.1371/journal.ppat.1002506. Epub 2012 Feb 2.</citation>
    <PMID>22319447</PMID>
  </reference>
  <reference>
    <citation>Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.</citation>
    <PMID>22865544</PMID>
  </reference>
  <reference>
    <citation>SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.</citation>
    <PMID>23323897</PMID>
  </reference>
  <reference>
    <citation>Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, Sinet M, Delfraissy JF, Meyer L, Goujard C, Rouzioux C; Frnech PRIMO Cohort Study Group. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS. 2001 Apr 13;15(6):665-73.</citation>
    <PMID>11371680</PMID>
  </reference>
  <reference>
    <citation>Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, Baker D, Bloch M, Murray JM, Zaunders J, Emery S, Cooper DA, Kelleher AD; PINT study team. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS. 2011 Nov 13;25(17):2069-78. doi: 10.1097/QAD.0b013e32834b9658. Erratum in: AIDS. 2012 Nov 28;26(18):2425. AIDS. 2012 Jul 17;26(11):1455.</citation>
    <PMID>21860347</PMID>
  </reference>
  <results_reference>
    <citation>Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One. 2012;7(8):e43754. Epub 2012 Aug 31.</citation>
    <PMID>22952756</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012 Sep 21;37(3):377-88. doi: 10.1016/j.immuni.2012.08.010. Review.</citation>
    <PMID>22999944</PMID>
  </results_reference>
  <results_reference>
    <citation>Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009 Nov;7(11):798-812. doi: 10.1038/nrmicro2223. Review.</citation>
    <PMID>19834480</PMID>
  </results_reference>
  <results_reference>
    <citation>Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS. 2012 Jun 19;26(10):1261-8. doi: 10.1097/QAD.0b013e328353f3f1. Review.</citation>
    <PMID>22472858</PMID>
  </results_reference>
  <results_reference>
    <citation>Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS. 2009 Sep 10;23(14):1799-806. doi: 10.1097/QAD.0b013e32832ec1dc.</citation>
    <PMID>19590405</PMID>
  </results_reference>
  <results_reference>
    <citation>Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009 Feb 12;360(7):692-8. doi: 10.1056/NEJMoa0802905.</citation>
    <PMID>19213682</PMID>
  </results_reference>
  <results_reference>
    <citation>Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14.</citation>
    <PMID>23516360</PMID>
  </results_reference>
  <results_reference>
    <citation>Deeks SG. HIV: Shock and kill. Nature. 2012 Jul 25;487(7408):439-40. doi: 10.1038/487439a.</citation>
    <PMID>22836995</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Cure</keyword>
  <keyword>Early Intervention</keyword>
  <keyword>Infection</keyword>
  <keyword>Primary infection</keyword>
  <keyword>Reservoir</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>HDAC</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

